Discovery of Novel Celastrol Derivatives as Hsp90–Cdc37 Interaction Disruptors with Antitumor Activity-Reference-Cited by-同舟云学术

Discovery of Novel Celastrol Derivatives as Hsp90–Cdc37 Interaction Disruptors with Antitumor Activity

Published:2019-11-14 Issue:23 Volume:62 Page:10798-10815
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Na¹,Xu Manyi¹,Wang Bing¹,Shi Zhixian¹,Zhao Zihao¹,Tang Yunqing¹,Wang Xinyue¹,Sun Jianbo¹,Chen Li¹^ORCID

Affiliation:

1. State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China

Funder

China Pharmaceutical University

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01290

Reference31 articles.

1. Unusual expression and localization of heat-shock proteins in human tumor cells

2. The Assembly of Progesterone Receptor-hsp90 Complexes Using Purified Proteins

3. The Cdc37 protein kinase–binding domain is sufficient for protein kinase activity and cell viability

4. Hsp90 and Cdc37 – a chaperone cancer conspiracy

5. Cdc37 as a Co-chaperone to Hsp90

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects;Journal of Medicinal Chemistry;2024-09-10

2. Scaffold Hopping of Pristimerin Provides Derivatives Containing a Privileged Quinoxaline Substructure as Potent Autophagy Inducers in Breast Cancer Cells;Journal of Natural Products;2024-08-06

3. Prodrug-inspired adenosine triphosphate–activatable celastrol-Fe(III) chelate for cancer therapy;Science Advances;2024-07-12

4. Celastrol Regulates the Hsp90-NLRP3 Interaction to Alleviate Rheumatoid Arthritis;Inflammation;2024-06-14

5. Discovery of new Hsp90–Cdc37 protein–protein interaction inhibitors: in silico screening and optimization of anticancer activity;RSC Advances;2024